scholarly journals Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C

2014 ◽  
Vol 35 ◽  
pp. 11-17 ◽  
Author(s):  
Nicole M. Welch ◽  
Donald M. Jensen
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Genotype 1 ◽  
Direct Acting Antivirals ◽  
Direct Acting ◽  
Second Wave

scholarly journals Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam

2020 ◽  
Vol 23 (9) ◽  
pp. 1180-1190 ◽  
Author(s):  
Ong The Due ◽  
Ammarin Thakkinstian ◽  
Montarat Thavorncharoensap ◽  
Abhasnee Sobhonslidsuk ◽  
Olivia Wu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Genotype 1 ◽  
Direct Acting Antivirals ◽  
Utility Analysis ◽  
Direct Acting

scholarly journals Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Ong The Due ◽  
Usa Chaikledkaew ◽  
Anne Julienne M. Genuino ◽  
Abhasnee Sobhonslidsuk ◽  
Ammarin Thakkinstian
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Meta Analysis ◽  
Pegylated Interferon ◽  
Efficacy And Safety ◽  
Direct Acting Antivirals ◽  
Hepatitis C Infection ◽  
Statistical Program ◽  
Direct Acting

Direct-acting antivirals (DAAs) are modern treatments for chronic hepatitis C infection, but majority of available evidence on its treatment effect covers genotypes 1 to 4. Therefore, the efficacy and safety of DAAs for genotypes 5 and 6 need to be analysed. Studies were identified from Medline, Scopus, and CENTRAL and a Chinese database CNKI, from inception until Dec 4, 2018. Clinical trials were included if they enrolled patients with genotypes 5 and/or 6 infection, any type of second-generation DAAs was studied, and sustained virological response was assessed at the 12th week after treatment (SVR12) as outcome measure. Meta-analysis using metaprop statistical program was applied for pooling proportions if data were sufficient (i.e., at least 2 studies). Thirteen studies were included in the analysis. Four studies assessed the efficacy of four DAA regimens in genotype 5 patients, which were mainly sofosbuvir (SOF) plus pegylated-interferon/ribavirin (PR) or other DAAs, with SVR12 ranging from 94.4% to 100%. Twelve studies assessed the efficacy of seven DAA regimens among genotype 6 patients, but only two DAA regimens (i.e., SOF + PR and SOF/ledipasvir) had sufficient data for pooling. The pooled SVR12 rates (95% CI) were 99.6% (92.2 to 100) for SOF + PR and 99.2% (96.5 to 100) for SOF/ledipasvir. No treatment-related serious adverse event was reported, while the nonserious adverse events were comparable to other genotypes. In conclusion, DAAs are effective and may be safe for the treatment of chronic hepatitis C genotypes 5 and 6. However, our evidence is based on noncomparative studies; hence, further larger-scale randomized controlled trials in these genotypes are still required.

Sign in / Sign up

Export Citation Format

Share Document